Indivior Pharmaceuticals Inc
INDV
Category
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 12.03 | -98.53% |
| 2024 | 820.38 | -22.76% |
| 2023 | 1.06K | -1,927.89% |
| 2022 | -58.10 | -574.05% |
| 2021 | 12.26 | -279.49% |
| 2020 | -6.83 | -350.23% |
| 2019 | 2.73 | -26.98% |
| 2018 | 3.74 | -94.26% |
| 2017 | 65.10 | -18.35% |
| 2016 | 79.73 | 0.00% |
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 34.96 | 190.64% |
IN
|
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.